Trial Profile

Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psoralen based cancer therapeutics-Immunolight (Primary)
Indications Advanced breast cancer; Head and neck cancer; Malignant melanoma; Soft tissue sarcoma; Squamous cell cancer
Focus Adverse reactions
Sponsors Immunolight

30 Jan 2026 Planned number of patients changed from 20 to 52.
17 Dec 2025 Planned End Date changed from 1 Mar 2026 to 1 Mar 2029.
17 Dec 2025 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com